

**carbinoxamine 6 mg tablet (RYVENT)**

**Diagnosis Considered for Coverage:**

- Prevention and reduction of symptoms associated with allergies

**Coverage Criteria:**

**For diagnosis listed above:**

- Dose not to exceed the FDA label maximum, **and**
- Medical rationale provided why patient is unable to use the carbinoxamine 4 mg tablet and oral suspension formulations.

**Coverage Duration:** one year

Effective Date: 09/27/2023